Eli Lilly and Company (BVL:LLYUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 3.75T +68.2% |
| Revenue (ttm) | 272.04B +49.6% |
| Net Income | 91.21B +93.6% |
| EPS | 101.72 +94.8% |
| Shares Out | n/a |
| PE Ratio | 41.10 |
| Forward PE | 31.50 |
| Dividend | 23.38 (0.55%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 32 |
| Open | 1,277.00 |
| Previous Close | 1,267.00 |
| Day's Range | 1,277.00 - 1,277.00 |
| 52-Week Range | 687.90 - 1,285.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Continues
The drug maker is seeing accelerating sales of its weight-loss medications.
Eli Lilly files six new lawsuits in effort to shutdown retatrutide black market
Eli Lilly (LLY) escalated its continued fight to protect patients from the black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to havi...
OmniAb announces collaboration and license agreement with Eli Lilly
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly and Company (LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expert...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)
The legal battle has erupted as competition between the companies intensifies.
Novo Nordisk Stock (NVO) Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly
Shares in Danish drugmaker Novo Nordisk ($NVO) fell about 2% to roughly $46 per share early Thursday. The decline came even though CEO Mike Doustar told Reuters in an interview…
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-tak...
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO Mike Doustdar defended the drugmaker's decision to sue rival Eli Lilly over its weight-loss drug advertising. "I am a big fan of competition.
Eli Lilly (LLY) Sues Six Companies Over Weight-Loss Drug Sales
The company is cracking down on illegal sales of its drugs.
Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide
Some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits for access to compounded versions of retatrutide.
Eli Lilly (LLY) Sues Six U.S. Firms Over Black Market Sales of Unapproved Obesity Drug
Eli Lilly & Co. ($LLY), the manufacturer of weight-loss drugs Mounjaro and Zepbound, has filed six lawsuits against U.S. businesses for illegally selling versions of its experimental drug retatrutide....
Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs
Eli Lilly has filed six new lawsuits against U.S. entities that it alleges are selling a version of the company's investigational weight-loss drug on the black market.
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Eli Lilly on Wednesday said it had filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide, escalating its campaig...
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patie...
Eli Lilly’s (LLY) Weight-Loss Pill Is Approved for Sale in the United Kingdom
It is the first regulatory approval for the medication outside the U.S.
Veeva says Eli Lilly has committed to Veeva Vault CRM globally
Veeva Systems (VEEV) announced that Eli Lilly and Company (LLY) has committed to Veeva Vault CRM globally. Vault CRM is part of the Vault CRM Suite of applications that provides…
Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.
Eli Lilly's Foundayo won U.K. approval, becoming Europe's second GLP-1 weight-loss pill and its first approval outside the U.S. Foundayo will initially be available privately by prescription, with NHS...
MHRA authorizes Eli Lilly’s weight loss pill Foundayo in UK
Britain’s Medicines and Healthcare products Regulatory Agency has authorized Eli Lilly’s (LLY) orforglipron, or Foundayo, making the UK the first country in Europe to approve this GLP-1 tablet for wei...
Five-Star Analyst Raises Price Target on Eli Lilly Stock (LLY) After Blowout Earnings
The company continues to see strong sales of its weight-loss drugs.
UK green lights Lilly's obesity pill
The British medicines regulator on Monday authorised Eli Lilly's pill Foundayo for weight management and type 2 diabetes, becoming Europe's first country to do so.
Nvidia, Eli Lilly, and Disney Show It's Time to Back the Top Dogs
Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now.
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows
The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulatio...